Work

Zongertinib combination therapy in HER2-positive metastatic breast cancer (mBC): First results from a phase Ib/II trial.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.1044

Authors: Shigehisa Kitano, Matteo Simonelli, Ramon Yarza, Jian Zhang, Min Yan, Qingyuan Zhang, Giuseppe Curigliano, Farshid Dayyani, Norikazu Masuda, Andrea Hahn-Kreienbring, Anna Hester, Kerstin Moeldner, Anke Baum, Patrizia Sini, Sila Aykut Yazgili, Damijan Erzen, Sara A. Hurvitz

Institutions: Japanese Foundation For Cancer Research, Humanitas University, IRCCS Humanitas Research Hospital, Shanghai Medical College of Fudan University, Fudan University, Fudan University Shanghai Cancer Center, Zhengzhou University, Henan Cancer Hospital, Third Affiliated Hospital of Harbin Medical University, University of Milan, European Institute of Oncology, University of California, Irvine, Kyoto University, Boehringer Ingelheim (Germany), Boehringer Ingelheim (Austria), University of Washington, Fred Hutch Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162571850

Cites:

Cited by:

Related to: